Innocan Pharma Corp. (INNPF): Valuation
TTM figures as of June 30, 2026
Innocan Pharma Corp. trades at a 1,184.51% free-cash-flow yield. That FCF yield is higher than 100% of its own month-end history back to 2020.
Earnings yield -133.56%. Shareholder yield 566.64%. ROIC 2.1%. Net debt $1.3B.
70 month-end valuation observations are on file, starting November 2020.
Sector comparison uses 1048 Consumer Defensive names.
Frequently asked questions
Is INNPF cheap versus its own history?
Innocan Pharma Corp. trades at a 1,184.51% free-cash-flow yield. That FCF yield is higher than 100% of its own month-end history back to 2020.
What is INNPF's free-cash-flow yield?
Innocan Pharma Corp. currently yields 1,184.51% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.